WEBINAR - March 7, 2024 at 1pm ET – Rethinking therapeutic response assessment in clinical trials using ultra-sensitive ctDNA – new data and promising applications

Register now

News & Publications

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design


Back to all